CN105612183A - 结合尿激酶纤溶酶原激活物的抗体 - Google Patents

结合尿激酶纤溶酶原激活物的抗体 Download PDF

Info

Publication number
CN105612183A
CN105612183A CN201480040491.0A CN201480040491A CN105612183A CN 105612183 A CN105612183 A CN 105612183A CN 201480040491 A CN201480040491 A CN 201480040491A CN 105612183 A CN105612183 A CN 105612183A
Authority
CN
China
Prior art keywords
upa
antibody
seq
kabat
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201480040491.0A
Other languages
English (en)
Chinese (zh)
Inventor
S.帕德克杰
J.帕斯
G.罗德
K.阿姆霍特
P.A.厄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN105612183A publication Critical patent/CN105612183A/zh
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/972—Plasminogen activators
    • G01N2333/9723—Urokinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201480040491.0A 2013-07-15 2014-07-15 结合尿激酶纤溶酶原激活物的抗体 Withdrawn CN105612183A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13176519.0 2013-07-15
EP13176519 2013-07-15
US201361847664P 2013-07-18 2013-07-18
US61/847664 2013-07-18
PCT/EP2014/065136 WO2015007727A1 (en) 2013-07-15 2014-07-15 Antibodies that bind urokinase plasminogen activator

Publications (1)

Publication Number Publication Date
CN105612183A true CN105612183A (zh) 2016-05-25

Family

ID=48783103

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480040491.0A Withdrawn CN105612183A (zh) 2013-07-15 2014-07-15 结合尿激酶纤溶酶原激活物的抗体

Country Status (6)

Country Link
US (1) US9908944B2 (https=)
EP (1) EP3022229A1 (https=)
JP (1) JP2016527225A (https=)
CN (1) CN105612183A (https=)
TW (1) TW201536810A (https=)
WO (1) WO2015007727A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110343665A (zh) * 2019-05-05 2019-10-18 吉林大学 一种新型car-t细胞及其应用
CN111253486A (zh) * 2018-09-27 2020-06-09 再鼎医药(上海)有限公司 抗pd-1抗体及其用途
WO2022171196A1 (zh) * 2021-02-11 2022-08-18 兰州大学第二医院 抗cd87抗体及其特异性嵌合抗原受体
CN115135673A (zh) * 2019-10-28 2022-09-30 莫纳什大学 用于结合纤溶酶的抗体

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
AU2018219887B2 (en) 2017-02-08 2024-08-15 Dragonfly Therapeutics, LLC Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CN110944661A (zh) 2017-02-20 2020-03-31 蜻蜓疗法股份有限公司 结合her2、nkg2d和cd16的蛋白质
EP3459974B1 (en) * 2017-09-21 2025-02-19 Guy L. Reed Specific plasmin inactivation by anticatalytic antibody
BR112020015994A2 (pt) 2018-02-08 2020-12-15 Dragonfly Therapeutics, Inc. Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer
CA3237846A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
WO2019164930A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
KR102835308B1 (ko) 2018-08-08 2025-07-21 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
JP7512394B2 (ja) 2020-05-06 2024-07-08 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
US20250332277A1 (en) * 2024-04-26 2025-10-30 Eli Lilly And Company Protein tyrosine kinase 7 antibodies and antibody-drug conjugates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453269A (en) 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
TW212184B (https=) 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
US8062637B2 (en) 2000-05-08 2011-11-22 Morphosys Ag Methods of ameliorating inflammatory disease using an uPA antagonist
US20030096733A1 (en) 2001-07-10 2003-05-22 Omnio Ab Novel drug targets for arthritis
EP3960855A1 (en) * 2001-12-28 2022-03-02 Chugai Seiyaku Kabushiki Kaisha Method for stabilizing proteins
US20050232924A1 (en) 2003-11-18 2005-10-20 Attenuon Llc Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
EP1814914A2 (en) 2004-10-29 2007-08-08 The Regents of the University of Colorado Antibodies that bind urokinase-type plasminogen activator and epitopes therefor
PT1876236E (pt) * 2005-04-08 2014-10-22 Chugai Pharmaceutical Co Ltd Anticorpos para substituição da função do factor de coagulação sanguínea viii
US8628773B2 (en) * 2011-04-07 2014-01-14 Amgen Inc. Antigen binding proteins

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111253486A (zh) * 2018-09-27 2020-06-09 再鼎医药(上海)有限公司 抗pd-1抗体及其用途
CN111253486B (zh) * 2018-09-27 2023-09-29 再鼎医药(上海)有限公司 抗pd-1抗体及其用途
CN110343665A (zh) * 2019-05-05 2019-10-18 吉林大学 一种新型car-t细胞及其应用
CN115135673A (zh) * 2019-10-28 2022-09-30 莫纳什大学 用于结合纤溶酶的抗体
WO2022171196A1 (zh) * 2021-02-11 2022-08-18 兰州大学第二医院 抗cd87抗体及其特异性嵌合抗原受体

Also Published As

Publication number Publication date
JP2016527225A (ja) 2016-09-08
US20160159924A1 (en) 2016-06-09
US9908944B2 (en) 2018-03-06
TW201536810A (zh) 2015-10-01
WO2015007727A1 (en) 2015-01-22
EP3022229A1 (en) 2016-05-25

Similar Documents

Publication Publication Date Title
US9908944B2 (en) Antibodies that bind urokinase plasminogen activator
JP7764565B2 (ja) プラスミノーゲン活性化因子阻害剤－１（ｐａｉ－１）に対する抗体及びその使用
JP5774312B2 (ja) ヒト化抗ヒトｎｋｇ２ａモノクローナル抗体
JP6126532B2 (ja) 抗ｉｌ−２３抗体
TWI564305B (zh) 治療性抗體
CN111386285B (zh) 增强fx活化的因子x结合物
CA2977621C (en) Antibody binding to tfpi and composition comprising the same
JP2009541449A (ja) 抗ｎｋｇ２ａ抗体とその使用
CN112334486B (zh) 用于治疗癌症的组合物和方法
MX2010012142A (es) Anticuerpos para receptor de productos finales de glucacion avanzada (rage) y usos de los mismos.
AU2014261398A1 (en) Monoclonal antibody directed against CXCR5
JP2024522237A (ja) ヒトフィブリンまたはフィブリノゲンγＣドメインに結合する抗体および使用方法
CN105473619B (zh) 能够引起促凝血活性的识别组织因子途径抑制剂的n-末端部分的抗体
TWI858383B (zh) 一種ｃｄｃ平臺抗體
JP2026514054A (ja) デュアル阻害性トリプシン抗体及びその使用
KR20260028191A (ko) 이중 억제제 트립신 항체 및 이의 용도
CN121311502A (zh) 激肽释放酶抗体以及其用途
HK40040395B (zh) 用於治疗癌症的组合物和方法
HK40040395A (en) Compositions and methods for treating cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20160525

WW01 Invention patent application withdrawn after publication